Johnson & Johnson (JNJ) Interest Coverage Ratio (2009 - 2026)
Johnson & Johnson recorded quarterly Interest Coverage Ratio of 23.39 in Q1 2026, down 75.05% quarter-over-quarter from 93.75 in Q4 2025, and down 22.8% year-over-year from 30.3 in Q1 2025.
Johnson & Johnson's Interest Coverage Ratio history runs 18 years deep, the most recent figure standing at 23.39 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 22.8% year-over-year to 23.39; the TTM figure through Mar 2026 stood at 38.6 (up 45.78% YoY), while the FY2025 annual figure was 41.12, up 47.72% from the prior year.
- Interest Coverage Ratio came in at 23.39 for Q1 2026 at Johnson & Johnson, down from 93.75 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 435.2 in Q2 2022 to a low of 21.58 in Q2 2025.
- A 5-year average of 72.04 and a median of 29.9 in 2023 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio surged 315.73% in 2022 and slumped 93.8% in 2023, its largest moves.
- Johnson & Johnson's Interest Coverage Ratio stood at 103.9 in 2022, then increased by 20.17% to 124.85 in 2023, then tumbled by 78.96% to 26.27 in 2024, then soared by 256.88% to 93.75 in 2025, then slumped by 75.05% to 23.39 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 23.39, 93.75, and 28.71 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 23.39 |
| Dec 28, 2025 | 93.75 |
| Sep 28, 2025 | 28.71 |
| Jun 29, 2025 | 21.58 |
| Mar 30, 2025 | 30.30 |
| Dec 29, 2024 | 26.27 |
| Sep 29, 2024 | 26.10 |
| Jun 30, 2024 | 23.96 |
| Mar 31, 2024 | 38.12 |
| Dec 31, 2023 | 124.85 |
| Oct 1, 2023 | 29.90 |
| Jul 2, 2023 | 26.79 |
| Apr 2, 2023 | 26.96 |
| Jan 1, 2023 | 62.80 |
| Oct 2, 2022 | 103.90 |
| Jul 3, 2022 | 102.08 |
| Apr 3, 2022 | 435.20 |
| Oct 3, 2021 | 330.30 |
| Jul 4, 2021 | 155.05 |
| Apr 4, 2021 | 104.68 |
| Jan 3, 2021 | 93.61 |
| Sep 27, 2020 | 131.16 |
| Jun 28, 2020 | 88.80 |
| Mar 29, 2020 | 231.52 |
| Dec 29, 2019 | 48.13 |
| Sep 29, 2019 | 121.25 |
| Jun 30, 2019 | 64.49 |
| Mar 31, 2019 | 51.89 |
| Dec 30, 2018 | 15.96 |
| Sep 30, 2018 | 22.71 |
| Jul 1, 2018 | 21.13 |
| Apr 1, 2018 | 21.70 |
| Dec 31, 2017 | 10.82 |
| Oct 1, 2017 | 19.78 |
| Jul 2, 2017 | 23.26 |
| Apr 2, 2017 | 26.29 |
| Jan 1, 2017 | 13.65 |
| Oct 2, 2016 | 27.47 |
| Jul 3, 2016 | 29.29 |
| Apr 3, 2016 | 33.22 |
| Sep 27, 2015 | 37.75 |
| Jun 28, 2015 | 37.53 |
| Mar 29, 2015 | 38.74 |
| Dec 28, 2014 | 28.37 |
| Sep 28, 2014 | 42.90 |
| Jun 29, 2014 | 46.64 |
| Mar 30, 2014 | 41.51 |
| Dec 29, 2013 | 30.39 |
| Sep 29, 2013 | 46.43 |
| Jun 30, 2013 | 42.93 |
| Mar 31, 2013 | 39.55 |
| Dec 30, 2012 | 38.80 |
| Sep 30, 2012 | 31.88 |
| Jul 1, 2012 | 32.17 |
| Apr 1, 2012 | 31.05 |
| Jan 1, 2012 | 5.93 |
| Oct 2, 2011 | 29.25 |
| Jul 3, 2011 | 28.98 |
| Apr 3, 2011 | 36.81 |
| Oct 3, 2010 | 37.24 |
| Jul 4, 2010 | 42.53 |
| Apr 4, 2010 | 44.14 |
| Jan 3, 2010 | 23.62 |
| Sep 27, 2009 | 30.02 |
| Jun 28, 2009 | 39.58 |
| Mar 29, 2009 | 43.86 |